Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Tx Treated With Cesium-131 GammaTile®

NCT: NCT07821112 · NOT_YET_RECRUITING

NCT IDNCT07821112
StatusNOT_YET_RECRUITING
Start Date2026-10
Completion2029-10
SponsorUniversity of California, Irvine (OTHER)
First posted
Last updated

Brief Summary

This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.

Frequently Asked Questions

What is Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Tx Treated With Cesium-131 GammaTile®?

Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Tx Treated With Cesium-131 GammaTile® is a clinical trial registered under NCT07821112. Current status: NOT_YET_RECRUITING.

What is the status of NCT07821112?

The current status of NCT07821112 (Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Tx Treated With Cesium-131 GammaTile®) is: NOT_YET_RECRUITING.

When did Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Tx Treated With Cesium-131 GammaTile® start?

Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Tx Treated With Cesium-131 GammaTile® started on 2026-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑